We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply to: Comments on "Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045".
- Authors
Kim, Yoo‐Na; Joung, Je‐Gun; Park, Eunhyang; Kim, Jae‐Weon; Lee, Jung Bok; Lim, Jinyeong; Kim, Sunghoon; Choi, Chel Hun; Kim, Hee Seung; Chung, Jongsuk; Kim, Byoung‐Gie; Lee, Jung‐Yun
- Abstract
This document is a reply to comments on a study that investigated the use of poly-ADP ribose polymerase (PARP) inhibitor-based combinations in ovarian cancer with homologous recombination repair (HRR) mutations. The authors agree with the importance of exploring biomarkers to improve therapy response and overcome resistance in platinum-resistant ovarian cancer. They clarify that the high objective response rate (ORR) in their study was influenced by the inclusion of patients with BRCA mutations. The document suggests further research to improve outcomes for patients with non-BRCA, HRR mutations, including the exploration of novel targeted agents and triplet combinations. The authors also mention recent studies that demonstrate promising results with triplet maintenance regimens.
- Subjects
OVARIAN cancer; HOMOLOGOUS recombination; OLAPARIB; RIBOSE; BRCA genes; CA 125 test
- Publication
International Journal of Cancer, 2024, Vol 154, Issue 4, p764
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.34786